171 related articles for article (PubMed ID: 12495901)
1. Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: results of a prospective randomized trial.
Dallorso S; Rondelli R; Messina C; Pession A; Giorgiani G; Fagioli F; Locatelli F; Manzitti C; Balduzzi A; Prete A; Cesaro S; Lanino E; Dini G
Haematologica; 2002 Dec; 87(12):1274-80. PubMed ID: 12495901
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
3. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
4. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation.
de Azevedo AM; Nucci M; Maiolino A; Vigorito AC; Simões BP; Aranha FJ; Tabak DG; Voltarelli J; de Souza CA
Bone Marrow Transplant; 2002 May; 29(9):745-51. PubMed ID: 12040471
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage.
Oza A; Hallemeier C; Goodnough L; Khoury H; Shenoy S; Devine S; Augustin K; Vij R; Trinkaus K; Dipersio JF; Adkins D
Transfusion; 2006 Jan; 46(1):14-23. PubMed ID: 16398726
[TBL] [Abstract][Full Text] [Related]
6. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
7. Administration of erythopoietin and granulocyte colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor cells (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC transplantation.
Sautois B; Baudoux E; Salmon JP; Michaux S; Schaaf-Lafontaine N; Pereira M; Paulus JM; Fillet G; Beguin Y
Haematologica; 2001 Nov; 86(11):1209-18. PubMed ID: 11694408
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
[TBL] [Abstract][Full Text] [Related]
9. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
[TBL] [Abstract][Full Text] [Related]
10. G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day.
Bolwell B; Goormastic M; Dannley R; Andresen S; Overmoyer B; Mendez Z; Kalaycioglu M; DeMars D; Wise K; Pohlman B
Bone Marrow Transplant; 1997 Feb; 19(3):215-9. PubMed ID: 9028548
[TBL] [Abstract][Full Text] [Related]
11. Progenitor content of autologous grafts: mobilized bone marrow vs mobilized blood.
Dahl E; Burroughs J; DeFor T; Verfaillie C; Weisdorf D
Bone Marrow Transplant; 2003 Sep; 32(6):575-80. PubMed ID: 12953129
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of recombinant human granulocyte colony-stimulating factor in children undergoing bone marrow transplantation.
Dini G; Floris R; Pession A; Manfredini L; Dallorso S; Lanino E; Garaventa A; Miano M; Kotitsa Z; Rondelli R
Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():121-8. PubMed ID: 8932813
[TBL] [Abstract][Full Text] [Related]
13. Pilot trial of combined administration of erythropoietin and granulocyte colony-stimulating factor to children undergoing allogeneic bone marrow transplantation.
Locatelli F; Zecca M; Ponchio L; Beguin Y; Giorgiani G; Maccario R; Bonetti F; De Stefano P; Cazzola M
Bone Marrow Transplant; 1994 Dec; 14(6):929-35. PubMed ID: 7536073
[TBL] [Abstract][Full Text] [Related]
14. [Collection of hematopoietic progenitor cells from healthy donors].
Bojanić I; Cepulić BG; Mazić S
Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
[TBL] [Abstract][Full Text] [Related]
15. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies.
Vicent MG; Madero L; Chamorro L; Madero R; Diaz MA
Haematologica; 2001 Oct; 86(10):1087-94. PubMed ID: 11602415
[TBL] [Abstract][Full Text] [Related]
16. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
Broers AE; van der Holt B; Haze S; Braakman E; Gratama JW; Löwenberg B; Cornelissen JJ
Exp Hematol; 2005 Aug; 33(8):912-9. PubMed ID: 16038784
[TBL] [Abstract][Full Text] [Related]
17. Delayed administration of filgrastim (G-CSF) following autologous peripheral blood stem cell transplantation (APBSCT) in pediatric patients does not change time to neutrophil engraftment and reduces use of G-CSF.
Pai V; Fernandez SA; Laudick M; Rosselet R; Termuhlen A
Pediatr Blood Cancer; 2010 May; 54(5):728-33. PubMed ID: 20063422
[TBL] [Abstract][Full Text] [Related]
18. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
[TBL] [Abstract][Full Text] [Related]
19. Serum granulocyte colony-stimulating factor (G-CSF) levels after allogeneic T cell-depleted marrow transplantation.
Papadakis V; Diaz-Barrientos T; Heller G; Collins NH; McKeever S; Kernan NA
Bone Marrow Transplant; 1995 Jun; 15(6):955-61. PubMed ID: 7581097
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
